Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

Arrhythmia Research Converts Predictor Into Customizable Modular Product

Arrhythmia Research Technology, (ART or the company) has converted its signal-averaged electrocardiography (SAECG) software Predictor that will run on a single hardware based platform, ART 1200-EPX, to a customizable modular software product that is reconfigurable for a variety of hardware platforms.

The conversion allows Predictor to be used with customer-specific electrocardiogram acquisition equipment to generate the signal-averaged ECG. The software can be easily customized to interface with a variety of original equipment manufacturer (OEM) hardware. OEM customers can license Predictor and bundle it with other cardiac diagnostic software packages incorporated in their acquisition equipment.

A signal-averaged electrocardiogram detects cardiac microvolt signals. High resolution acquisition equipment is used to collect the microvolt signals and transfer the data to an analytical system. The patented Predictor software embedded in the system then filters and analyzes the data to present the signal-averaged ECG for interpretation by a cardiologist.

James Rouse, president and CEO of Arrhythmia Research Technology, said: “We are pleased to announce the availability of the Predictor SAECG analysis software to the OEM market. The patented methodology used in Predictor is considered by the American College of Cardiology and the American Heart Association to be the ‘Gold Standard’ in signal-averaged electrocardiography analysis.

“It is a valuable risk stratification tool for electrophysiologists and cardiologists in the management of post myocardial infarction patients. Predictor is currently being used in a National Institutes for Health (NIH) funded investigation into ‘Risk Stratification in MADIT II Type Patients’.”

Wojciech Zareba, principal investigator of the NIH study at the University of Rochester, said: “It is likely that SAECG and Microvolt T-Wave Alternans tests will emerge as routine for identifying low-risk and high-risk patients considered for ICD therapy. Results from this study are expected to be forthcoming in late 2011.”